Lexaria Bioscience (LEXX) has released an update.
Lexaria Bioscience has commissioned a third human pilot study to test the oral capsule form of DehydraTECH-processed tirzepatide, a diabetes treatment currently only available as an injection (Zepbound® by Eli Lilly). The study will assess the drug’s absorption and effects on blood sugar levels, with the aim of offering a potentially more tolerable oral medication alternative for patients. Lexaria anticipates a significant breakthrough if the oral delivery of tirzepatide shows measurable bloodstream absorption and improved tolerability.
For further insights into LEXX stock, check out TipRanks’ Stock Analysis page.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
